1. Scrip
  2. >>Business

Moderna Plans Big R&D Cut As Profitability Guidance Pushed Out

FDA Pushes Back On mRNA-4157 Accelerated Approval

 
• By Alaric DeArment

The biotech saw its shares plunge more than 12% after an R&D day, where it announced it would push a breakeven target from 2026 to 2028.

• Source: Shutterstock

Moderna, Inc. touted multiple development programs at its R&D day, but the event was not as positive as investors hoped as it also pushed back the timeline to becoming profitable, announced a large cut in R&D spending and reported a lack of enthusiasm from the US Food and Drug Administration for an accelerated approval filing of its Merck & Co., Inc.-partnered melanoma cancer vaccine.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.